Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

Earnings season is now well under way, with a number of major companies due to release results in the coming week. Investors ...

Shares of newly public Metsera (MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Read more here.

Your favorite toys and weight-loss drugs could be priced out of reach if Donald Trump is serious. Denmark’s defiant message ...

Donald Trump has on several occasions floated the idea of buying Greenland, the autonomous Danish territory. However, there is no shortage of economic leverage for Denmark to hurt the United States.

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans at risk for kidney failure.

Danish drugmaker Novo Nordisk's shares hit an over 9-month low ... next year overshadowed strong sales growth for its popular Wegovy weight-loss drug.

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...